Fernanda Mosele received her MD from the Universidad of Buenos Aires in 2007. She then pursued specialised training in Clinical Oncology at the Universidad Católica Argentina in Buenos Aires.

Dr. Mosele worked as a medical oncologist in Buenos Aires and dedicated her expertise to patient care until 2018, when her passion for translational research led her to join the renowned Gustave Roussy in Villejuif. At Gustave Roussy, she initially collaborated with the breast cancer unit under the guidance of Professor Fabrice André, focusing on the prognosis and treatment outcomes of patients with metastatic breast cancer and PIK3CA mutations. Her commitment to precision medicine subsequently grew, leading her to collaborate with the ESMO Precision Medicine Working Group. In 2020, she played a pivotal role in formulating recommendations for the utilisation of next-generation sequencing (NGS) in the treatment of metastatic cancers, a seminal work published the same year. Dr. Mosele further honed her expertise in precision medicine through postgraduate studies at the Université Paris-Saclay.

Currently, Dr. Mosele is at the forefront of biomarker research and precision medicine. She is an integral part of a comprehensive institutional programme dedicated to clinical and translational research on antibodies-drug conjugates and drug development. Dr. Mosele recently published a pioneering study in Nature Medicine as the lead author, unraveling the mechanisms of action and resistance to trastuzumab deruxtecan. Additionally, she leads phase I-III clinical trials evaluating targeted therapies for advanced breast cancer.